Clinical trials: Advanced Head and Neck Cancer
Advanced Solid Tumor
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
- Trial name
- NCT04349267
- Testing
- BMS-986315, nivolumab, cetuximab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Head or Neck Cancer
Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
This phase II study will test the response rate of combined oxaliplatin and capecitabine treatment when administered at a given dose and schedule, in patients with Head and Neck cancer for which there is no curative treatment.
- Trial name
- NCT00266279
- Testing
- Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Louisville
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Esophageal Cancer, Gastric Cancer
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Anti-angiogenic therapy is a proven therapeutic target in refractory gastric and gastroesophageal junction adenocarcinoma. This trial assessed whether the addition of a high affinity angiogenesis inhibitor, ziv-aflibercept, could…
- Trial name
- NCT01747551
- Testing
- Oxaliplatin, Leucovorin, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma, Head and Neck Cancer
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.
- Conditions
- Squamous Cell Carcinoma, Head and Neck Cancer, Recurrent Disease
- Trial name
- NCT01794845
- Testing
- Erbitux, Taxotere, Low Dose Fractionated Radiation Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Priming Immunotherapy in Advanced Disease With Radiation
This study proposes to treat metastatic non-small cell lung cancer (NSCLC) and head/neck squamous cell cancer (HNSCC) patients who are already initiating an immune checkpoint inhibitor (such as Nivolumab, Atezolizumab or…
- Trial name
- NCT03313804
- Testing
- Immune checkpoint inhibitor, Radiation Therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- John L. Villano, MD, PhD
Head and Neck Cancer
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
The purpose of this study is to explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer.
- Trial name
- NCT01185171
- Testing
- ZD 1839 500mg
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.
- Conditions
- Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell, Advanced Solid Tumors
- Trial name
- NCT02834247
- Testing
- TAK-659, Nivolumab
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- Calithera Biosciences, Inc
Squamous Cell Carcinoma
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis…
- Trial name
- STARRS (NCT02213133)
- Testing
- Selinexor (KPT-330)
- Where
- 18 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Karyopharm Therapeutics Inc
Head and Neck Cancer, Cancer of the Pharynx
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
For advanced head and neck cancer, combined radiation and chemotherapy prevents recurrences and for many patients, improves survival.
- Conditions
- Head and Neck Cancer, Cancer of the Pharynx, Cancer of the Larynx, Nose Neoplasms
- Trial name
- NCT00462735
- Testing
- Cetuximab, Hydroxyurea, Fluorouracil
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johnny Kao
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Cancer
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
This is a Phase 1 / Phase 2 study of newly diagnosed patients with biopsy-proven head and neck cancer (squamous cell carcinoma) who are undergoing standard radiation therapy and treatment with cisplatin.
- Trial name
- BMX-HN (NCT02990468)
- Testing
- BMX-001, Radiation Therapy, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioMimetix JV, LLC
Head and Neck Cancer
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
- Trial name
- NCT01412229
- Testing
- Cetuximab, Nab-paclitaxel, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Thyroid Cancer
A Study of E7080 in Subjects With Advanced Thyroid Cancer
This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally administered once daily (QD) in subjects with advanced thyroid cancer.
- Trial name
- NCT01728623
- Testing
- E7080 capsule
- Where
- 3 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Eisai Co., Ltd.
Esophageal Cancer, Squamous Cell Esophagus Cancer
Pembrolizumab in Refractory Advanced Esophageal Cancer
This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab
- Conditions
- Esophageal Cancer, Squamous Cell Esophagus Cancer, Adenocarcinoma Esophagus
- Trial name
- NCT02971956
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
This partially randomized phase I/II trial studies the side effects and best dose of veliparib when given together with combination chemotherapy and to see how well they work in treating patients with stage IV head and neck…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7
- Trial name
- NCT01711541
- Testing
- Carboplatin, Cisplatin, Fluorouracil
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Gastric Cancer
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT02318329
- Testing
- FPA144
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 79 people
- Sponsor
- Five Prime Therapeutics, Inc.
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
This phase II trial investigates how well sodium thiosulfate works in preventing ototoxicity (hearing loss/damage) in patients with squamous cell cancer of the head and neck that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04541355
- Testing
- Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hyunseok Kang, MD